[go: up one dir, main page]

BRPI0800585B8 - composições farmacêuticas do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7) e uso do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7) - Google Patents

composições farmacêuticas do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7) e uso do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7)

Info

Publication number
BRPI0800585B8
BRPI0800585B8 BRPI0800585A BRPI0800585A BRPI0800585B8 BR PI0800585 B8 BRPI0800585 B8 BR PI0800585B8 BR PI0800585 A BRPI0800585 A BR PI0800585A BR PI0800585 A BRPI0800585 A BR PI0800585A BR PI0800585 B8 BRPI0800585 B8 BR PI0800585B8
Authority
BR
Brazil
Prior art keywords
ala1
angiotensin
des
asp1
peptide
Prior art date
Application number
BRPI0800585A
Other languages
English (en)
Inventor
José Ferreira Anderson
Augusto Souza Dos Santos Robson
Dario Sinisterra Ruben
Original Assignee
Univ Minas Gerais
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minas Gerais filed Critical Univ Minas Gerais
Priority to BRPI0800585A priority Critical patent/BRPI0800585B8/pt
Priority to EP09841273.7A priority patent/EP2264048B1/en
Priority to PCT/BR2009/000046 priority patent/WO2009100513A2/pt
Priority to US12/867,599 priority patent/US9974825B2/en
Priority to CN2009801089471A priority patent/CN102124023A/zh
Publication of BRPI0800585A2 publication Critical patent/BRPI0800585A2/pt
Publication of BRPI0800585B1 publication Critical patent/BRPI0800585B1/pt
Publication of BRPI0800585B8 publication Critical patent/BRPI0800585B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/14—Angiotensins: Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

peptídio des-[asp1i-[ala1]- agonista da angiotensina-(1-7) e composições farmacêuticas para tratamento de doenças a presente invenção relaciona-se ao uso do peptídio des-[asp1]-[aia1j-angiotensina-(1-7) (ala1-arg2-vai3-tyr4-llle5-his6-pro7) e/ou compostos relacionados como agentes vasculoprotetores e cardioprotetores em mamíferos. a invenção compreende ainda a obtenção de composições contendo des-[asp1]-[ala1)-angiotensina-(1-7) e/ou compostos relacionados e seu uso em métodos para tratamento ou prevenção de doenças.
BRPI0800585A 2008-02-13 2008-02-13 composições farmacêuticas do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7) e uso do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7) BRPI0800585B8 (pt)

Priority Applications (5)

Application Number Priority Date Filing Date Title
BRPI0800585A BRPI0800585B8 (pt) 2008-02-13 2008-02-13 composições farmacêuticas do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7) e uso do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7)
EP09841273.7A EP2264048B1 (en) 2008-02-13 2009-02-13 Peptide des-[asp1]-[ala1],angiotensin-(1-7) agonist and pharmaceutical compounds for the treatment of diseases
PCT/BR2009/000046 WO2009100513A2 (pt) 2008-02-13 2009-02-13 Peptideo des-[asp1hala1]- agonista da angiotensina-(1 -7) e composiҫões farmacêuticas para tratamento de doenças
US12/867,599 US9974825B2 (en) 2008-02-13 2009-02-13 Peptides Des-[Asp1]-[Ala1], angiotensin-(1-7) agonist and pharmaceutical compositions for the treatment of diseases
CN2009801089471A CN102124023A (zh) 2008-02-13 2009-02-13 用于疾病治疗的肽Des-[ASP1]-[ALA1],血管紧张素-(1-7)激动剂和药物组合物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0800585A BRPI0800585B8 (pt) 2008-02-13 2008-02-13 composições farmacêuticas do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7) e uso do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7)

Publications (3)

Publication Number Publication Date
BRPI0800585A2 BRPI0800585A2 (pt) 2010-12-28
BRPI0800585B1 BRPI0800585B1 (pt) 2019-10-22
BRPI0800585B8 true BRPI0800585B8 (pt) 2021-05-25

Family

ID=40957305

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0800585A BRPI0800585B8 (pt) 2008-02-13 2008-02-13 composições farmacêuticas do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7) e uso do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7)

Country Status (5)

Country Link
US (1) US9974825B2 (pt)
EP (1) EP2264048B1 (pt)
CN (1) CN102124023A (pt)
BR (1) BRPI0800585B8 (pt)
WO (1) WO2009100513A2 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0800585B8 (pt) 2008-02-13 2021-05-25 Univ Minas Gerais composições farmacêuticas do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7) e uso do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7)
EP2455388A1 (en) 2010-11-23 2012-05-23 LanthioPep B.V. Novel angiotensin type 2 (AT2) receptor agonists and uses thereof.
BRPI1103387B1 (pt) * 2011-07-21 2022-04-19 Universidade Federal De Minas Gerais Composição farmacêutica para tratamento de hipertensão arterial baseada na co- administração de anti-hiperstensivos e angiotensina (1-7) ou outro agonista do receptor mas
BR102013023224B1 (pt) * 2012-09-14 2023-02-07 Universidade Federal De Minas Gerais PEPTÍDEO (ARGº)N-ANGIOTENSINA-(1-7) E COMPOSIÇÕES FARMACÊUTICAS PARA TRATAMENTO DE DOENÇAS
CA2884792A1 (en) * 2012-09-17 2014-03-20 Tarix Pharmaceuticals Ltd. Oral formulations of angiotensin
US8633158B1 (en) * 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
WO2014078929A1 (pt) * 2012-11-26 2014-05-30 Universidade Federal De Minas Gerais - Ufmg Formulações tópicas para a prevenção e tratamento da alopecia e para inibição do crescimento de pêlos
EP3003345A4 (en) 2013-05-24 2017-03-01 Tarix Pharmaceuticals Ltd. Angiotensin peptides in treating marfan syndrome and related disorders
CA2957211C (en) 2013-10-18 2022-07-05 Trustees Of The University Of Pennsylvania Oral delivery of angiotensin converting enzyme 2 (ace2) or angiotensin-(1-7) bioencapsulated in plant cells
AU2015294371B2 (en) 2014-07-21 2018-02-01 The Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) derivative oligopeptides and methods for using and producing the same
EP3350200A4 (en) 2015-09-18 2019-03-27 Wake Forest University Health Services ANGIOTENSIN (1 7) ANALOGUE AND ASSOCIATED PROCEDURES
US10960045B2 (en) 2015-10-14 2021-03-30 Constant Therapeutics Llc Methods and compositions for the treatment of epidermolysis bullosa
EP3565575B1 (en) * 2017-01-09 2023-03-08 The Arizona Board of Regents On Behalf of the University of Arizona Ang (1-7) derivative oligopeptides for the treatment of pain
US10987403B2 (en) * 2017-03-10 2021-04-27 University Of Southern California Cyclodextrin-Nle3-A(1-7) compositions and their use
EP3820498A1 (en) * 2018-06-14 2021-05-19 University College Cork-National University of Ireland Cork Peptide for disease treatment
EP4371556A1 (en) 2022-11-15 2024-05-22 Explicat Pharma GmbH Angiotensin(1-7) pharmaceutical compositions for inhalation
WO2025122594A1 (en) 2023-12-04 2025-06-12 Constant Therapeutics, Llc Improved methods and compositions for the treatment of pemphigus or pemphigoid disease
WO2025137668A1 (en) 2023-12-21 2025-06-26 Constant Therapeutics, Llc Methods and compositions for the treatment of optic neuropathy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110895A (en) * 1996-12-16 2000-08-29 University Of Southern California Method of promoting healing in skin grafts
WO2001078759A1 (en) * 2000-04-13 2001-10-25 National University Of Singapore The use of des-aspartate-angiotensin i as an agent for the treatment and prevention of glomerulosclerosis and renal failure
BR0102252B1 (pt) 2001-04-10 2013-10-22 Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso
US6589938B2 (en) * 2001-06-29 2003-07-08 National University Of Singapore Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders
BRPI0105509B8 (pt) * 2001-11-05 2021-05-25 Univ Minas Gerais formulações do peptídeo angiotensina-(1-7) usando as ciclodextrinas, lipossomas e o polímero plga
CA2475953A1 (en) * 2002-02-27 2003-09-04 E. Ann Tallant Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth
US20050119180A1 (en) * 2002-03-28 2005-06-02 Roks Antonius J.M. Use of angiotensin 1-7 for enhancing cardiac function
BRPI0502497A (pt) 2005-06-28 2007-02-06 Univ Minas Gerais uso de agonistas e antagonistas do receptor acoplado a proteìna g, mas, como moduladores de atividade apoptótica para o estudo, a prevenção e o tratamento de doenças
EP1931370B1 (en) * 2005-09-09 2015-07-08 National University of Singapore Use of des-aspartate-angiotensin i
BRPI0602366B1 (pt) 2006-04-26 2017-12-12 Universidade Federal De Minas Gerais Use of agonists of the receptor coupled to protein g, but, in the treatment of metabolic syndrome, its components and their complications
US8653031B2 (en) 2006-10-30 2014-02-18 Universidade Federal De Minas Gerais Process for the preparation of compositions of AT1 receptor antagonist and Angiotensin—(1-7)
EP2124991B1 (en) 2007-01-26 2013-11-27 Universidade Federal De Minas Gerais - UFMG Pharmaceutical compositions and methods for treating erectile dysfunction
BRPI0800585B8 (pt) 2008-02-13 2021-05-25 Univ Minas Gerais composições farmacêuticas do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7) e uso do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7)

Also Published As

Publication number Publication date
CN102124023A (zh) 2011-07-13
BRPI0800585B1 (pt) 2019-10-22
EP2264048B1 (en) 2016-07-13
EP2264048A4 (en) 2011-11-16
EP2264048A2 (en) 2010-12-22
WO2009100513A2 (pt) 2009-08-20
US9974825B2 (en) 2018-05-22
BRPI0800585A2 (pt) 2010-12-28
WO2009100513A3 (pt) 2009-11-05
US20130183367A1 (en) 2013-07-18

Similar Documents

Publication Publication Date Title
BRPI0800585B8 (pt) composições farmacêuticas do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7) e uso do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7)
NI201100082A (es) Compuestos de isoindolina para uso en el tratamiento de cáncer.
BR112012010706A2 (pt) composto, composição farmacêutica, combinação do produto farmacêutico, uso de um composto, e, métodos para o tratamento de uma doença ou condição, e para inibir um bromodomínio
BRPI0922220A8 (pt) Uso de compostos antibacterianos, composição farmacêutica e combinação compreendendo os mesmos
BR112013020586A2 (pt) Uso de células derivadas de tecido do cordão umbilical
BRPI0916286B8 (pt) amidofenóxi-indazóis úteis como inibidores de c-met, seus usos, e composição farmacêutica
BRPI0714803B8 (pt) compostos peptidomiméticos de smac, seus usos, e composição farmacêutica
BR112014015339A8 (pt) compostos para inibição da interação de bcl2 com parceiros de ligação
BR112012012918A8 (pt) Agente indutor de apoptose para o tratamento de câncer e de doenças imunes e autoimunes
BR112014000240A2 (pt) derivados de benzilamina como inibidores de calicreína plasmática
MY155649A (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
ATE465164T1 (de) Triazolopyrazinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
BR112013032774A2 (pt) métodos para tratar e prevenir infecções por staphylococcus aureus e condições associadas
EA201290184A1 (ru) Бензодиазепиновый ингибитор бромодомена
BR112013026032A2 (pt) composições nutricionais incluindo ácidos graxos de cadeia ramificada para cicatrização de ferida
BRPI0609393B8 (pt) usos de um composto 11-desóxi-prostaglandina
BRPI0810064B8 (pt) compostos contendo nitrogênio tricíclico como agentes antibacterianos, composições farmacêuticas que compreendem os ditos compostos e uso dos mesmos para o tratamento de infecções bacterianas em mamíferos
BRPI1007379B8 (pt) composições farmacêuticas para o tratamento ou prevenção de infecções orais por e. coli
UA108193C2 (uk) Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
BR112012022650A2 (pt) derivados de imidazo [1,2-a]pirazina e seu uso como inibidores de pde10
BR122014013631B8 (pt) compostos antivirais, seu uso e composição farmacêutica compreendendo os mesmos
BRPI0919447B8 (pt) compostos derivados de ácido 1-amino-2- ciclobutiletilborônico, composição farmacêutica e uso dos mesmos para tratar câncer
EA201001865A1 (ru) Противовоспалительные агенты
CL2011000119A1 (es) Compuestos derivados de triazolo[4,3-a]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
BR112014003063A2 (pt) "3,4-di-hidro-1h-[1,8]naftiridinonas substituídas com ciclopenta[c]pirrol antibacterianas, composição farmacêutica compreendendo os referidos compostos, processos para preparação destes e uso".

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08E Application fees: payment of additional fee required [chapter 8.5 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08G Application fees: restoration [chapter 8.7 patent gazette]
B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/10/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/02/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF